Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, ...

An artificial intelligence (AI)-driven machine learning model was refined and validated internationally to accurately classify acute leukemia subtypes from routine laboratory data, according to Merlin ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

Patients with low psoriasis body surface area (BSA) can have similar quality of life impacts and symptom burdens as those ...

In this clip, Adela Perolla, MD, PhD, discusses the urgent need to address and destigmatize burnout in hematology, especially among early-career professionals, by promoting self-awareness, work-life ...

The announcement of the new members of the CDC Advisory Committee on Immunization Practice comes days after the HHS secretary ...

Adela Perolla, MD, PhD, is a hematologist at the University Hospital Center "Mother Teresa" in Tirana, Albania.

Burnout is rising sharply in hematology due to emotional strain, long hours, and high patient demands, according to Adela Perolla, MD, PhD, impacting both physician well-being and patient care.

Panelists discuss how current therapeutic strengths include 15 approved treatments with different mechanisms of action that ...

Panelists discuss how emerging intrathecal gene therapy for older patients with spinal muscular atrophy (SMA) shows modest ...

Panelists discuss how comorbidities such as scoliosis, dislocated hips, and nutritional issues affect spinal muscular atrophy ...

Ola Landgren, MD, PhD, shares ADVANCE trial results, which show that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (DKRd) improves outcomes in newly diagnosed multiple myeloma.